JPH0761905A - Beautifully whitening cosmetic - Google Patents
Beautifully whitening cosmeticInfo
- Publication number
- JPH0761905A JPH0761905A JP21166593A JP21166593A JPH0761905A JP H0761905 A JPH0761905 A JP H0761905A JP 21166593 A JP21166593 A JP 21166593A JP 21166593 A JP21166593 A JP 21166593A JP H0761905 A JPH0761905 A JP H0761905A
- Authority
- JP
- Japan
- Prior art keywords
- karahanaenone
- oil
- derivative
- whitening cosmetic
- beautifully whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 16
- 230000002087 whitening effect Effects 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 239000006210 lotion Substances 0.000 abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract description 6
- SKKTZNHVYFHGDC-UHFFFAOYSA-N 2,2,5-trimethylcyclohept-4-en-1-one Chemical class CC1=CCC(C)(C)C(=O)CC1 SKKTZNHVYFHGDC-UHFFFAOYSA-N 0.000 abstract description 5
- 239000006071 cream Substances 0.000 abstract description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 abstract description 4
- 235000013871 bee wax Nutrition 0.000 abstract description 3
- 229940119170 jojoba wax Drugs 0.000 abstract description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 abstract description 3
- 229940032094 squalane Drugs 0.000 abstract description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 abstract description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 abstract description 2
- 229960000541 cetyl alcohol Drugs 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 244000025221 Humulus lupulus Species 0.000 abstract 1
- 235000008694 Humulus lupulus Nutrition 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- -1 monoterpene compound Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- NTBZFDJHZLAGRA-UHFFFAOYSA-N 3,6,6-trimethyl-7-oxocyclohept-3-ene-1-carboxylic acid Chemical compound CC1=CCC(C(=O)C(C1)C(=O)O)(C)C NTBZFDJHZLAGRA-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- CIYSPNNZYJRQPP-UHFFFAOYSA-N C1C(C)=CCC(C)(C)C(O)C1C(=O)NC1=CC=C(O)C=C1 Chemical compound C1C(C)=CCC(C)(C)C(O)C1C(=O)NC1=CC=C(O)C=C1 CIYSPNNZYJRQPP-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- QNMCKJKJVJJSAL-UHFFFAOYSA-N cyclohept-3-ene-1-carboxamide Chemical compound NC(=O)C1CCCC=CC1 QNMCKJKJVJJSAL-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は美白作用が高い化粧料に
関する。TECHNICAL FIELD The present invention relates to a cosmetic having a high whitening effect.
【0002】[0002]
【従来の技術】カラハナエノンはホップ油等より得られ
るモノテルペン化合物であり、香料においては重要な化
合物の1つである。カラハナエノンの化学構造式を次の
化3に示す。カラハナエノン自体には美白作用はない。Kalahana enone is a monoterpene compound obtained from hop oil and the like, and is one of the important compounds in perfume. The chemical structural formula of Kalahana enone is shown in Chemical Formula 3 below. Kalahana Enon itself has no whitening effect.
【化3】 [Chemical 3]
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、皮膚
に適用して安全であると共に、美白作用が大きい化粧料
を提供することである。SUMMARY OF THE INVENTION An object of the present invention is to provide a cosmetic which is safe when applied to the skin and has a large whitening effect.
【0004】[0004]
【課題を解決するための手段】本発明者らは前記の課題
を解決するため鋭意研究を行った結果、ホップ油から得
られるカラハナエノンについて、いろいろな誘導体を作
成して実験をしたところ下記の構造の誘導体物質が美白
作用が強く、化粧品原料として非常に有効であることを
検知し、本発明を完成した。これらの誘導体の作成方法
自体は公知の方法を用いて作成すればよい。Means for Solving the Problems As a result of intensive studies to solve the above-mentioned problems, the present inventors have prepared various derivatives of karahanaenone obtained from hop oil and conducted experiments to find the following structures. The present inventors have completed the present invention by detecting that the derivative substance of (1) has a strong whitening effect and is very effective as a raw material for cosmetics. A known method may be used to prepare these derivatives.
【0005】利用方法としては、この誘導体物質を他の
化粧料原料例えばスクワラン、ホホバ油等の液状油、ミ
ツロウ、セチルアルコール等の固体油、各種の活性剤、
グリセリン、1,3ブチレングリコール等の保湿剤や、
各種薬剤等を添加して、さまざまな剤形の化粧料を調製
することができる。例えばローション、クリーム、乳
液、パック等で目的に応じて利用形態を考えればよい。As a method of utilizing this derivative substance, other cosmetic materials such as liquid oils such as squalane and jojoba oil, solid oils such as beeswax and cetyl alcohol, various active agents,
Moisturizers such as glycerin and 1,3 butylene glycol,
Cosmetics of various dosage forms can be prepared by adding various drugs and the like. For example, a lotion, a cream, a milky lotion, a pack, or the like may be used depending on the purpose.
【0006】本発明の美白化粧料の美白有効成分である
カラハナエノンの誘導体の内で特に効果が大きいのは下
記の構造のものである。Among the derivatives of karahanaenanone, which is the active ingredient for whitening cosmetics of the whitening cosmetic composition of the present invention, those having the following structures are particularly effective.
【化4】 [Chemical 4]
【化5】 [Chemical 5]
【0007】[0007]
【製造例】以下に実際の誘導体の製造方法である製造例
を記載するが、本発明はこの製造例によって何等限定さ
れるものではない。[Manufacturing Example] The following describes a manufacturing example which is a method for manufacturing an actual derivative, but the present invention is not limited to this manufacturing example.
【0008】(製造例1) N−p−ヒドロキシフェニル−3,3,6−トリメチル
−5−シクロヘプタン−2−オン−1−カルボキシアミ
ド 窒素気流下、マグネチックスターラー及びセプタムキャ
ップを付した200mlの四つ口フラスコをドライアイス
−アセトン浴で冷却しつつ、1.64モル/リッター−
n−ブチルリチウム、ヘキサン溶液23.4mlを注入
し、さらに乾燥エーテルを20ml加えた。それにジイソ
プロピルアミン4.2gと乾燥エーテル10mlとの溶液
を50分間かけて滴下し、滴下後1時間撹拌した。撹拌
後、カラハナエノン5.0gと乾燥エーテル10mlとの
溶液を40分間かけて滴下し、滴下後1時間30分間撹
拌した。撹拌後、反応系内を二酸化炭素で置換した後、
霜がついていないドライアイス小片を撹拌しながら、3
0分間を要して投入した。その後、冷却浴をはずし、徐
々に室温に戻しながら30分間撹拌した。 反応終了
後、1規定塩酸100mlを加えて酸性とした後、酢酸エ
チル500mlで抽出し、水層が中性になるまで飽和食塩
水で洗浄した。有機層を無水硫酸ナトリウムで乾燥した
後、溶媒を減圧留去して粗生成物を得た。(Production Example 1) N-p-hydroxyphenyl-3,3,6-trimethyl-5-cycloheptan-2-one-1-carboxamide Under a nitrogen stream, 200 ml equipped with a magnetic stirrer and a septum cap. While cooling the four-necked flask of 1. in a dry ice-acetone bath, 1.64 mol / liter-
23.4 ml of n-butyllithium and a hexane solution were injected, and 20 ml of dry ether was further added. A solution of 4.2 g of diisopropylamine and 10 ml of dry ether was added dropwise thereto over 50 minutes, and the mixture was stirred for 1 hour after the addition. After stirring, a solution of 5.0 g of kalahananone and 10 ml of dry ether was added dropwise over 40 minutes, and after the addition, the mixture was stirred for 1 hour and 30 minutes. After stirring, after replacing the reaction system with carbon dioxide,
3 while stirring dry frost-free pieces of dry ice
It took 0 minutes and was charged. Then, the cooling bath was removed, and the mixture was stirred for 30 minutes while gradually returning to room temperature. After completion of the reaction, the mixture was acidified by adding 100 ml of 1N hydrochloric acid, extracted with 500 ml of ethyl acetate, and washed with saturated saline until the aqueous layer became neutral. After the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain a crude product.
【0009】さらに粗生成物をヌッチェ上で吸引しなが
らヘキサンで洗浄し、減圧下乾燥することにより、3,
3,6−トリメチル−5−シクロヘプテン−2−オン−
1−カルボン酸を得た。収量は5.57gであった。撹
拌器、塩化カルシウム管、滴下ロートを付した50mlの
四つ口フラスコに上記で得た3,3,6−トリメチル−
5−シクロヘプテン−2−オン−1−カルボン酸2.5
g及びヘキサメチルリン酸トリアミドを触媒量とり、氷
冷下で激しく撹拌しながら、塩化チオニル3.5mlを1
0分間かけて滴下し、滴下後40分間撹拌した。その
後、過剰の塩化チオニルを除くため減圧下で20分間撹
拌した。反応終了後、酢酸エチルで抽出し、常法通り操
作してβ−ケトカルボン酸クロリドの粗生成物を得た。Further, the crude product was washed with hexane while sucking on the Nutsche, and dried under reduced pressure to obtain 3,
3,6-Trimethyl-5-cyclohepten-2-one-
1-carboxylic acid was obtained. The yield was 5.57g. In a 50 ml four-necked flask equipped with a stirrer, a calcium chloride tube and a dropping funnel, 3,3,6-trimethyl-
5-Cyclohepten-2-one-1-carboxylic acid 2.5
g and hexamethylphosphoric triamide in catalytic amounts, and while vigorously stirring under ice cooling, 1 ml of thionyl chloride (3.5 ml) was added.
The mixture was added dropwise over 0 minutes and stirred for 40 minutes after the addition. Then, the mixture was stirred under reduced pressure for 20 minutes to remove excess thionyl chloride. After completion of the reaction, the reaction product was extracted with ethyl acetate and operated in a usual manner to obtain a crude product of β-ketocarboxylic acid chloride.
【0010】次に撹拌器、滴下ロートを付した50mlの
四つ口フラスコに酢酸10.2mlとp−アミノフェノー
ル1.5gを入れ、これに調製したβ−ケトカルボン酸
クロリドを室温で撹拌しながら20分間かけて滴下し
た。滴下終了後、酢酸ナトリウム水溶液(3.0g/1
2.5ml)を一度に加えてさらに1時間30分間撹拌し
た。反応終了後、酢酸エチルで抽出し、常法通り操作し
て粗生成物を得た。さらにシリカゲルカラムクロマトグ
ラフィー(200mesh、溶媒ヘキサン:酢酸エチル
=7:3)により精製してN−p−ヒドロキシフェニル
−3,3,6−トリメチル−5−シクロヘプテン−2−
オン−1−カルボキシアミドを収量2.8gで得た。Next, 10.2 ml of acetic acid and 1.5 g of p-aminophenol were placed in a 50 ml four-necked flask equipped with a stirrer and a dropping funnel, and the prepared β-ketocarboxylic acid chloride was stirred at room temperature. It dripped over 20 minutes. After completion of dropping, aqueous sodium acetate solution (3.0 g / 1
2.5 ml) was added in one portion and the mixture was further stirred for 1 hour and 30 minutes. After completion of the reaction, the reaction product was extracted with ethyl acetate and operated in a usual manner to obtain a crude product. Further, it was purified by silica gel column chromatography (200 mesh, solvent hexane: ethyl acetate = 7: 3), and Np-hydroxyphenyl-3,3,6-trimethyl-5-cycloheptene-2-
On-1-carboxamide was obtained in a yield of 2.8 g.
【0011】(製造例2) 2−ヒドロキシ−N−p−ヒドロキシフェニル−3,
3,6−トリメチル−5−シクロヘプテン−1−カルボ
キシアミド 撹拌器、塩化カルシウム管、滴下ロートを付した50ml
の四つ口フラスコに水素化ほう素ナトリウム0.2gと
無水エタノール2.0mlをとり、氷冷下で撹拌しなが
ら、製造例1のN−p−ヒドロキシフェニル−3,3,
6−トリメチル−5−シクロヘプテン−2−オン−1−
カルボキシアミドを1.0gを最少量の無水エタノール
に溶解し、30分間かけて滴下した。滴下終了後、室温
で1時間撹拌した。(Production Example 2) 2-hydroxy-Np-hydroxyphenyl-3,
3,6-trimethyl-5-cycloheptene-1-carboxamide 50ml with stirrer, calcium chloride tube, dropping funnel
Sodium borohydride (0.2 g) and anhydrous ethanol (2.0 ml) were placed in the four-necked flask described above and stirred under ice-cooling, and N-p-hydroxyphenyl-3,3,3 of Production Example 1 was stirred.
6-trimethyl-5-cyclohepten-2-one-1-
Carboxamide (1.0 g) was dissolved in the minimum amount of absolute ethanol and added dropwise over 30 minutes. After completion of dropping, the mixture was stirred at room temperature for 1 hour.
【0012】反応終了後、酢酸エチルで抽出し、常法通
り操作して粗生成物を得た。さらにシリカゲルカラムク
ロマトグラフィー(200mesh、溶媒ヘキサン:酢
酸エチル=9:1)により精製して2−ヒドロキシ−N
−p−ヒドロキシフェニル−3,3,6−トリメチル−
5−シクロヘプテン−1−カルボキシアミドを収量2.
0gで得た。After completion of the reaction, the reaction product was extracted with ethyl acetate and operated in a conventional manner to obtain a crude product. Further purified by silica gel column chromatography (200 mesh, solvent hexane: ethyl acetate = 9: 1) to give 2-hydroxy-N.
-P-hydroxyphenyl-3,3,6-trimethyl-
Yield of 5-cycloheptene-1-carboxamide 2.
Obtained in 0 g.
【0013】[0013]
【実施例1】 ローション (重量部) オリーブ油 0.5 製造例1のN−p−ヒドロキシフェニル−3,3,6 −トリメチル−5−シクロヘプテン−2−オン−1− カルボキシアミド 0.5 ポリオキシエチレン(20E.O.)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.O.)硬化ヒマシ油 2.0 エタノール 10.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 精製水 80.0Example 1 Lotion (parts by weight) Olive oil 0.5 Np-hydroxyphenyl-3,3,6-trimethyl-5-cyclohepten-2-one-1-carboxamide 0.5 polyoxy of Production Example 1 Ethylene (20E.O.) sorbitan monostearate 2.0 Polyoxyethylene (60E.O.) Hydrogenated castor oil 2.0 Ethanol 10.0 1.0% sodium hyaluronate aqueous solution 5.0 Purified water 80.0
【0014】[0014]
【実施例2】 クリーム A スクワラン 20.5 オリーブ油 2.0 ミンク油 1.0 ホホバ油 5.0 ミツロウ 5.0 セトステアリルアルコール 2.0 グリセリンモノステアレート 1.0 ソルビタンモノステアレート 2.0 製造例2の2−ヒドロキシ−N−p−ヒドロキシフェ ニル−3,3,6−トリメチル−5−シクロヘプテン −1−カルボキシアミド 0.5Example 2 Cream A Squalane 20.5 Olive Oil 2.0 Mink Oil 1.0 Jojoba Oil 5.0 Beeswax 5.0 Cetostearyl Alcohol 2.0 Glycerin Monostearate 1.0 Sorbitan Monostearate 2.0 Production 2-Hydroxy-N-p-hydroxyphenyl-3,3,6-trimethyl-5-cycloheptene-1-carboxamide of Example 2 0.5
【0015】 B 精製水 47.9 ポリオキシエチレン(20E.O.)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.O.)硬化ヒマシ油 1.0 グリセリン 5.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 パラオキシ安息香酸メチル 0.1 AとBをそれぞれ計量し、70℃まで加温し、BにAを
撹拌しつつ徐々に加えたのち、ゆっくり撹拌しつつ30
℃まで冷却した。B Purified water 47.9 Polyoxyethylene (20 E.O.) sorbitan monostearate 2.0 Polyoxyethylene (60 E.O.) hydrogenated castor oil 1.0 glycerin 5.0 1.0% hyaluronic acid Aqueous sodium solution 5.0 Methyl paraoxybenzoate 0.1 A and B were weighed and heated to 70 ° C., A was slowly added to B with stirring, and then 30 with slow stirring.
Cooled to ° C.
【0016】(チロシナーゼ活性阻害試験) (試験方法)30mMリン酸ナトリウム緩衝液(pH
6.8)1.8ml、1.66mMチロシン水溶液1.0
mlを37℃で恒温にしたのち、検体の15mMジメチル
スルホキシド溶液を0.1ml加えて撹拌後、チロシナー
ゼ水溶液(約900unit/ml)0.1mlを加え、撹
拌し、37℃に保ったまま475nmの波長でチロシナ
ーゼ水溶液添加後、1分後と11分後を測定した。対照
として、上記試験液のかわりにジメチルスルホキシド
0.1mlを加え同様に測定した。この試験では試料の終
濃度は0.5mMとなる。 (計算式) チロシナーゼ活性阻害率(%)=((B11-B1)−(A11-A1))
/(B11-B1)×100 但し A1:試料検体の1分後の吸光度 A11:試料検体の11分後の吸光度 B1:対照の1分後の吸光度 B11:対照の11分後の吸光度 その結果を表1に示す。(Tyrosinase activity inhibition test) (Test method) 30 mM sodium phosphate buffer (pH
6.8) 1.8 ml, 1.66 mM tyrosine aqueous solution 1.0
After incubating ml at 37 ° C, 0.1 ml of a 15 mM dimethylsulfoxide solution of the sample was added and stirred, and then 0.1 ml of an aqueous tyrosinase solution (about 900 unit / ml) was added, and the mixture was stirred and kept at 37 ° C at 475 nm. After the addition of the aqueous tyrosinase solution, the wavelength was measured 1 minute and 11 minutes later. As a control, 0.1 ml of dimethyl sulfoxide was added instead of the above test solution, and the same measurement was performed. In this test, the final concentration of the sample is 0.5 mM. (Calculation formula) Tyrosinase activity inhibition rate (%) = ((B11-B1)-(A11-A1))
/ (B11-B1) × 100 However, A1: Absorbance of sample specimen after 1 minute A11: Absorbance of sample specimen after 11 minutes B1: Absorbance after 1 minute of control B11: Absorbance after 11 minutes of control It shows in Table 1.
【0017】[0017]
【表1】 [Table 1]
【0018】(使用テスト)女性7名の顔面を左右に分
け、左方に実施例1,2のローションとクリームを使用
してもらい、右の方に比較例1,2のローションとクリ
ームを使用してもらって、3月後、その官能検査の結果
を下記の基準によりアンケートして、評点の合計値を求
めた。比較例1は実施例1より、製造例1の化合物を除
いたローション、比較例2は実施例2より、製造例2の
化合物を除いたクリームである。即ち実験No1は表2
のようになる。(Usage test) The faces of seven women were divided into left and right, the left side was used with the lotions and creams of Examples 1 and 2, and the right side was used with the lotions and creams of Comparative Examples 1 and 2. After three months, the sensory test results were surveyed according to the following criteria to obtain the total score. Comparative Example 1 is a lotion obtained by removing the compound of Production Example 1 from Example 1, and Comparative Example 2 is a cream obtained by removing the compound of Production Example 2 from Example 2. That is, the experiment No1 is shown in Table 2
become that way.
【0019】[0019]
【表2】 [Table 2]
【0020】判定基準は以下のようでアンケートの結果
の合計値をもとめたのが以下の表3である。 実施例の方が非常によい 3 実施例の方がかなりよい 2 実施例の方がややよい 1 差がない 0 比較例の方がややよい −1 比較例の方がかなりよい −2 比較例の方が非常によい −3The judgment criteria are as follows, and Table 3 below shows the total values of the questionnaire results. Example is very good 3 Example is considerably good 2 Example is slightly good 1 No difference 0 Comparative example is good −1 Comparative example is good −2 Comparative example Is very good -3
【0021】[0021]
【表3】 [Table 3]
【0022】[0022]
【発明の効果】チロシナーゼ活性阻害試験よりみても、
又使用テストの結果よりみても、本発明のカラハナエノ
ン誘導体は優れた美白作用を有することが明らかになっ
た。化粧料に配合して優れた美白化粧品とし得る。[Effect of the invention] From the tyrosinase activity inhibition test,
Also, the results of the usage test revealed that the Kalahana enone derivative of the present invention has an excellent whitening effect. An excellent whitening cosmetic product can be obtained by blending with cosmetics.
Claims (2)
料。1. A whitening cosmetic containing a derivative of kalahana enone.
に示す構造である請求項1記載のカラハナエノンの誘導
体を含む美白化粧料。 【化1】 【化2】 2. A whitening cosmetic composition containing a Kalahana enone derivative according to claim 1, wherein the Kalahana enone derivative has a structure shown below. [Chemical 1] [Chemical 2]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21166593A JP3233505B2 (en) | 1993-08-26 | 1993-08-26 | Whitening cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21166593A JP3233505B2 (en) | 1993-08-26 | 1993-08-26 | Whitening cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0761905A true JPH0761905A (en) | 1995-03-07 |
JP3233505B2 JP3233505B2 (en) | 2001-11-26 |
Family
ID=16609572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP21166593A Expired - Fee Related JP3233505B2 (en) | 1993-08-26 | 1993-08-26 | Whitening cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3233505B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2772607A1 (en) * | 1997-12-19 | 1999-06-25 | Oreal | USE OF AMINO PHENOL AMINO DERIVATIVES AS DEPIGMENTING AGENTS |
FR2802416A1 (en) * | 1999-12-20 | 2001-06-22 | Oreal | COSMETIC COMPOSITION COMPRISING AN AMINOPHENOL DERIVATIVE |
JP2008179546A (en) * | 2007-01-23 | 2008-08-07 | Fuso Pharmaceutical Industries Ltd | Novel longicyclene derivative and tyrosinase activity inhibitor containing the derivative |
WO2012051741A1 (en) | 2010-10-22 | 2012-04-26 | 新钰生技股份有限公司 | Glycin derivatives inhibiting melanin production and whitening composition thereof |
CN105902423A (en) * | 2016-04-15 | 2016-08-31 | 欧标(广州)化妆品有限公司 | Whitening mask composition for uniformizing skin color and brightening skin |
-
1993
- 1993-08-26 JP JP21166593A patent/JP3233505B2/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2772607A1 (en) * | 1997-12-19 | 1999-06-25 | Oreal | USE OF AMINO PHENOL AMINO DERIVATIVES AS DEPIGMENTING AGENTS |
WO1999032077A1 (en) * | 1997-12-19 | 1999-07-01 | L'oreal | Use of amino phenol amide derivatives as depigmentation agents |
US6365135B1 (en) | 1997-12-19 | 2002-04-02 | L'oreal | Use of amino phenol amide derivatives as depigmentation agents |
FR2802416A1 (en) * | 1999-12-20 | 2001-06-22 | Oreal | COSMETIC COMPOSITION COMPRISING AN AMINOPHENOL DERIVATIVE |
EP1110538A3 (en) * | 1999-12-20 | 2004-01-02 | L'oreal | Cosmetic composition comprising an aminophenol derivative |
US7056498B2 (en) | 1999-12-20 | 2006-06-06 | L'oreal | Composition containing aminophenol derivative, use thereof, and process for dissolving aminophenol derivative |
JP2008179546A (en) * | 2007-01-23 | 2008-08-07 | Fuso Pharmaceutical Industries Ltd | Novel longicyclene derivative and tyrosinase activity inhibitor containing the derivative |
WO2012051741A1 (en) | 2010-10-22 | 2012-04-26 | 新钰生技股份有限公司 | Glycin derivatives inhibiting melanin production and whitening composition thereof |
CN105902423A (en) * | 2016-04-15 | 2016-08-31 | 欧标(广州)化妆品有限公司 | Whitening mask composition for uniformizing skin color and brightening skin |
Also Published As
Publication number | Publication date |
---|---|
JP3233505B2 (en) | 2001-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0325540B1 (en) | Aromatic esters and thioesters, process for their preparation and their use in human or animal therapeutics and in cosmetics | |
RU2121995C1 (en) | Polyene compounds and pharmaceutical and cosmetic compositions based thereon | |
EP0832081B1 (en) | Bicyclic-aromatic compounds | |
EP0342055B1 (en) | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | |
EP0879814A1 (en) | Triaromatic compounds, compositions containing them and uses thereof | |
CH662559A5 (en) | 2,6-DISUBSTITUTED NAPHTHALENE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING THEM. | |
RU2125554C1 (en) | Bi-aromatic acetylene compounds with adamantyl group, pharmaceutical and cosmetic composition based thereon | |
EP0292348B1 (en) | Polycyclic heterocyclic derivatives, proces for their preparation and their use in human and veterinary medicines | |
US3836665A (en) | Dermatological compositions containing certain higher alkyl esters of 5-pyrrolidone-(2)-carboxylic acid | |
EP0722928B1 (en) | Bicyclic-aromatic compounds with strong biologic activity, pharmaceutical and cosmetic compositions containing them and uses thereof | |
KR100349043B1 (en) | (poly)thiaalkynoic compounds and their derivatives, compositions comprising them and their use | |
CN102238948A (en) | Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | |
EP0977749B1 (en) | Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same | |
EP0658553B1 (en) | Polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | |
EP0728739B1 (en) | Biaromatic amide derivatives, pharmaceutical and cosmetic compositions containing them and their utilisations | |
CA2037150C (en) | Retinoids | |
JPH0761905A (en) | Beautifully whitening cosmetic | |
PT1456160E (en) | Vitamin d analogues | |
KR100503631B1 (en) | Retinol derivatives and process for preparing same | |
US5084579A (en) | Benzofuran compounds | |
JP5696159B2 (en) | NOVEL PEROXIDE DERIVATIVES, METHOD FOR PREPARATION THEREOF, AND ITS USE IN HUMAN MEDICALS AND COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | |
JP3545097B2 (en) | Skin cosmetics | |
US4898883A (en) | 1-Substituted derivatives of 4-methoxy-2,3,6-trimethylbenzene, process for their preparation and medicinal and cosmetic compositions containing them | |
JPH08502521A (en) | 10-Substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceutical | |
JP5613776B2 (en) | Novel peroxide derivatives, methods for their preparation and use in human pharmaceuticals and cosmetics to treat or prevent acne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100921 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |